newsdarolutamidemetastatic hormone-sensitive prostate cancer
Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens
By MedXY|Oct 30, 2025
This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balanc
